EMPA L 25/5 TABLET

EMPA L 25/5 TABLET is a pharmaceutical product that combines two active ingredients: Empagliflozin and Linagliptin. Each tablet contains 25mg of Empagliflozin and 5mg of Linagliptin. Empagliflozin belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. This combination medication is used to manage blood sugar levels in individuals with type 2 diabetes mellitus.

Uses:

EMPA L 25/5 TABLET is primarily used for the following purposes:

1. Type 2 Diabetes: It is used to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin works by inhibiting the reabsorption of glucose by the kidneys, leading to increased urinary glucose excretion. Linagliptin, on the other hand, works by inhibiting the enzyme DPP-4, which helps regulate blood sugar levels.

Side Effects:

EMPA L 25/5 TABLET is generally well-tolerated. However, like other medications, it may cause certain side effects in some individuals. Common side effects may include:

1. Genital Infections: SGLT2 inhibitors like Empagliflozin may increase the risk of genital infections, such as urinary tract infections and yeast infections.
2. Hypoglycemia: When used in combination with other antidiabetic medications such as insulin or sulfonylureas, EMPA L tablet may increase the risk of hypoglycemia (low blood sugar). This is more likely to occur if the dosage of the other antidiabetic medications is not adjusted appropriately.
3. Increased Urination and Thirst: The action of Empagliflozin in increasing urinary glucose excretion may lead to increased urination and thirst.
4. Gastrointestinal Effects: Nausea, diarrhea, and abdominal discomfort may occur in some cases.
5. Allergic Reactions: Allergic reactions to either Empagliflozin or Linagliptin, although rare, can occur and may manifest as skin rash, itching, swelling, or other signs of an allergic response.

If any unexpected or severe side effects occur while using EMPA L 25/5 TABLET, it is advisable to discontinue its use and consult a healthcare professional.

When Not to Use:

EMPA L 25/5 TABLET should not be used under certain conditions or circumstances, including:

1. Type 1 Diabetes: It is not indicated for the treatment of type 1 diabetes.
2. Allergy: If you have a known allergy or hypersensitivity to Empagliflozin, Linagliptin, or any other ingredients present in the tablet, it is recommended to avoid its use.
3. Diabetic Ketoacidosis: EMPA L tablet is contraindicated in individuals with diabetic ketoacidosis, a serious complication of diabetes.
4. Severe Renal Impairment: It should be used with caution or avoided in individuals with severe renal impairment or end-stage renal disease.
5. Pregnancy and Breastfeeding: It is important to consult with a healthcare professional before using EMPA L 25/5 TABLET during pregnancy or while breastfeeding to assess the potential risks and benefits.

It is essential to follow the prescribed dosage and consult with a healthcare professional if you have any concerns or specific medical conditions before using EMPA L 25/5 TABLET. Regular monitoring of blood sugar levels and periodic evaluation by a healthcare professional is recommended during the use of this medication.